A Senate panel is urging several federal agencies to undertake a series of moves, which include providing ways to test marijuana products sold at dispensaries in states where cannabis is legal.
Based on concerns over the lack of information on the potency and purity of cannabis being sold to consumers, the U.S. Senate Appropriations Committee is directing federal agencies to formulate a “National Testing Program for Schedule I Marijuana-Derived Products,” according to Forbes.
In a recent report, senators instructed scientists at the National Institute on Drug Abuse (NIDA) to work with the DEA to analyze marijuana samples and “provide robust reliable data that can inform policy.”
Until recently, research scientists analyzed illegal drugs provided by the government under a NIDA-funded program of testing samples of illicit marijuana seized by law enforcement.
This is the first move to officially analyze commercial cannabis products sold to consumers in legal marijuana states.
“The Committee believes that such research [on law-enforcement-seized cannabis], along with analysis of marijuana and marijuana-derived products sold commercially in dispensaries or online, is essential for informing substance abuse prevention efforts, public health policy, and law enforcement tactics across the Federal Government,” according to the report.
Tom Angell of the Marijuana Majority says it is not yet understood how the program will be carried out. Will NIDA research teams be dispatched to dispensaries to buy weed and analyze it or will they rely on DEA raids and confiscations of facilities then test the seized products?
In tin cans full of joints, NIDA distributed hundreds of pounds of weed in machine-rolled doobies to a handful of researchers for over 30 years, as a part of their Compassionate Investigational New Drug program.
So, with their experience in analyzing bad weed seized in pot busts or possibly worse weed grown for the government at the University of Mississippi, the feds might soon be testing cannabis consumed legally by real people.
Separately in the report, the committee also expressed alarm at the “barriers to research,” which are the result of cannabis being a Schedule 1 drug. The committee directed NIDA to compile a report about the matter.
“The Committee is concerned that restrictions associated with Schedule 1 of the Controlled Substance Act effectively limit the amount and type of research that can be conducted on certain Schedule 1 drugs, especially marijuana or its component chemicals and certain synthetic drugs,” the report says. “At a time when we need as much information as possible about these drugs, we need to review lowering regulatory and other barriers to conducting this research. The Committee directs NIDA to provide an update… on the barriers to research that result from the classification of drugs and compounds as Schedule 1 substances.”
New Jersey Lawmakers Draft New and Improved Marijuana Legalization Bill
Canadian Cannabis Company Tilray to Export Products to United States
Woman Finds Package of Weed in Food Subscription Box
South African Court Rules Private, Adult-Use Cannabis is Legal
Guides6 days ago
What To Do With Leftover Marijuana Stems
Entertainment5 days ago
Inside the Ignite Launch with Dan Bilzerian
News5 days ago
U.S. Congressional Committee Approves Cannabis Bill, But Not Without Drama
Celebrities6 days ago
Neil deGrasse Tyson on Elon Musk: ‘Let the Man Get High’
News5 days ago
Willie Nelson to Headline Rally for Pro-Cannabis Candidate Beto O’Rourke
News6 days ago
Manhattan DA Drops Over 3,000 Open Marijuana Cases Dating Back to 1978
News4 days ago
Washington, DC Sees Mass Synthetic Marijuana Overdose
News4 days ago
US Senate Candidate Gary Johnson Admits to Involvement in Cannabis Industry